A Study to Evaluate Intact FGF23 Performance in Patients with Tumor-induced Osteomalacia (TIO) and X-linked Hypophosphatemia (XLH)
Rochester, MN
The purpose of this study is to establish the clinical performance of the Medfrontier Intact FGF23 immunoassay in patients with tumor induced osteomalacia (TIO) and X-linked hypophosphatemia (XLH).